{
  "pmid": "29161201",
  "uid": "29161201",
  "title": "Reply to M. Mo et al.",
  "abstract": "",
  "authors": [
    {
      "last_name": "Shah",
      "fore_name": "Manish A",
      "initials": "MA",
      "name": "Manish A Shah",
      "affiliations": [
        "Manish A. Shah, Meyer Cancer Center at Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, New York, NY; Luis A. Herráaez-Baranda, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Amit Garg, Genentech, South San Francisco, CA; and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain."
      ]
    },
    {
      "last_name": "Herráez-Baranda",
      "fore_name": "Luis A",
      "initials": "LA",
      "name": "Luis A Herráez-Baranda",
      "affiliations": [
        "Manish A. Shah, Meyer Cancer Center at Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, New York, NY; Luis A. Herráaez-Baranda, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Amit Garg, Genentech, South San Francisco, CA; and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain."
      ]
    },
    {
      "last_name": "Garg",
      "fore_name": "Amit",
      "initials": "A",
      "name": "Amit Garg",
      "affiliations": [
        "Manish A. Shah, Meyer Cancer Center at Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, New York, NY; Luis A. Herráaez-Baranda, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Amit Garg, Genentech, South San Francisco, CA; and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain."
      ]
    },
    {
      "last_name": "Tabernero",
      "fore_name": "Josep",
      "initials": "J",
      "name": "Josep Tabernero",
      "affiliations": [
        "Manish A. Shah, Meyer Cancer Center at Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, New York, NY; Luis A. Herráaez-Baranda, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Amit Garg, Genentech, South San Francisco, CA; and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain."
      ]
    }
  ],
  "journal": {
    "title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
    "iso_abbreviation": "J Clin Oncol",
    "issn": "1527-7755",
    "issn_type": "Electronic",
    "volume": "36",
    "issue": "3",
    "pub_year": "2018",
    "pub_month": "Jan",
    "pub_day": "20"
  },
  "start_page": "303",
  "pages": "303",
  "language": "eng",
  "publication_types": [
    "Letter",
    "Comment"
  ],
  "keywords": [
    "Adenocarcinoma",
    "Esophagogastric Junction",
    "Humans",
    "Receptor, ErbB-2",
    "Trastuzumab"
  ],
  "article_ids": {
    "pubmed": "29161201",
    "doi": "10.1200/JCO.2017.75.2758"
  },
  "doi": "10.1200/JCO.2017.75.2758",
  "dates": {
    "completed": "2019-07-05",
    "revised": "2019-07-05"
  },
  "chemicals": [
    "ERBB2 protein, human",
    "Receptor, ErbB-2",
    "Trastuzumab"
  ],
  "grants": [],
  "search_metadata": {
    "search_type": "all_publications",
    "retrieved_date": "2025-07-30T14:22:09.236607",
    "pmid": "29161201"
  }
}